久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Doctors Accuse NextSource Biotech for Hiking the Price on Key Cancer Drug Nine Times

biospaceDecember 29, 2017

Tag: drug prices , NextSource

The cost of a vital cancer drug has gone up 15-fold in four years after its new owner hiked prices on nine separate occasions.

Lomustine has been used to treat brain tumours, lung cancer and Hodgkin’s lymphoma for more than 40 years but is now seen by some patients as too expensive.

In 2013, production of the drug, which was previously called CeeNU, passed from pharma giant Bristol-Myers Squibb to a Miami-based startup called NextSource Biotechnology.

Previous:Todd Campbell notes?four biopharma stocks that topped out in the S&P 5

Next:Amneal Pharmaceuticals welcomes new President Robert Stewart

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

PharmaSources Customer Service